Cargando…
Comparison of anti-inflammatory effect of atorvastatin with rosuvastatin in patients of acute coronary syndrome
OBJECTIVES: To compare anti-inflammatory effect of atorvastatin and rosuvastatin in patients of acute coronary syndrome. MATERIALS AND METHODS: The study was a prospective, open-labeled, randomized and single-center study conducted on 100 patients of acute coronary syndrome. Patients were assigned t...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4544133/ https://www.ncbi.nlm.nih.gov/pubmed/26311995 http://dx.doi.org/10.4103/0976-500X.162011 |
_version_ | 1782386646802497536 |
---|---|
author | Khurana, Sushant Gupta, Surabhi Bhalla, HiraLal Nandwani, Shefali Gupta, Varad |
author_facet | Khurana, Sushant Gupta, Surabhi Bhalla, HiraLal Nandwani, Shefali Gupta, Varad |
author_sort | Khurana, Sushant |
collection | PubMed |
description | OBJECTIVES: To compare anti-inflammatory effect of atorvastatin and rosuvastatin in patients of acute coronary syndrome. MATERIALS AND METHODS: The study was a prospective, open-labeled, randomized and single-center study conducted on 100 patients of acute coronary syndrome. Patients were assigned to atorvastatin 40 mg daily or rosuvastatin 20 mg daily for 4 weeks. C-reactive protein (CRP) levels, lipid profiles, erythrocyte sedimentation rate (ESR) and adverse effects were measured at beginning and at the end of 4 weeks. RESULTS: Baseline parameters and clinical profile did not differ between the two groups. CRP levels significantly decreased from beginning to the end of 4 weeks in both atorvastatin and rosuvastatin groups (from 35.48 to 23.07 mg/l and from 35.88 to 19.91 mg/l respectively, both P < 0.001). However, there was significant difference between the levels of CRP in patients of the rosuvastatin group as compared to the atorvastatin group (19.91 ± 6.32 vs 23.07 ± 7.47, P < 0.05). In addition, both the drugs were associated with a reduction in total cholesterol, LDL levels and ESR at the end of 4 weeks as compared to the beginning (P < 0.001 for all comparisons). CONCLUSION: Both atorvastatin (40 mg) and rosuvastatin (20 mg) are effective in decreasing CRP and LDL cholesterol levels even in a short duration of 4 weeks. Rosuvastatin was found to be more effective in decreasing CRP levels. |
format | Online Article Text |
id | pubmed-4544133 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Medknow Publications & Media Pvt Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-45441332015-08-26 Comparison of anti-inflammatory effect of atorvastatin with rosuvastatin in patients of acute coronary syndrome Khurana, Sushant Gupta, Surabhi Bhalla, HiraLal Nandwani, Shefali Gupta, Varad J Pharmacol Pharmacother Research Paper OBJECTIVES: To compare anti-inflammatory effect of atorvastatin and rosuvastatin in patients of acute coronary syndrome. MATERIALS AND METHODS: The study was a prospective, open-labeled, randomized and single-center study conducted on 100 patients of acute coronary syndrome. Patients were assigned to atorvastatin 40 mg daily or rosuvastatin 20 mg daily for 4 weeks. C-reactive protein (CRP) levels, lipid profiles, erythrocyte sedimentation rate (ESR) and adverse effects were measured at beginning and at the end of 4 weeks. RESULTS: Baseline parameters and clinical profile did not differ between the two groups. CRP levels significantly decreased from beginning to the end of 4 weeks in both atorvastatin and rosuvastatin groups (from 35.48 to 23.07 mg/l and from 35.88 to 19.91 mg/l respectively, both P < 0.001). However, there was significant difference between the levels of CRP in patients of the rosuvastatin group as compared to the atorvastatin group (19.91 ± 6.32 vs 23.07 ± 7.47, P < 0.05). In addition, both the drugs were associated with a reduction in total cholesterol, LDL levels and ESR at the end of 4 weeks as compared to the beginning (P < 0.001 for all comparisons). CONCLUSION: Both atorvastatin (40 mg) and rosuvastatin (20 mg) are effective in decreasing CRP and LDL cholesterol levels even in a short duration of 4 weeks. Rosuvastatin was found to be more effective in decreasing CRP levels. Medknow Publications & Media Pvt Ltd 2015 /pmc/articles/PMC4544133/ /pubmed/26311995 http://dx.doi.org/10.4103/0976-500X.162011 Text en Copyright: © Journal of Pharmacology and Pharmacotherapeutics http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Paper Khurana, Sushant Gupta, Surabhi Bhalla, HiraLal Nandwani, Shefali Gupta, Varad Comparison of anti-inflammatory effect of atorvastatin with rosuvastatin in patients of acute coronary syndrome |
title | Comparison of anti-inflammatory effect of atorvastatin with rosuvastatin in patients of acute coronary syndrome |
title_full | Comparison of anti-inflammatory effect of atorvastatin with rosuvastatin in patients of acute coronary syndrome |
title_fullStr | Comparison of anti-inflammatory effect of atorvastatin with rosuvastatin in patients of acute coronary syndrome |
title_full_unstemmed | Comparison of anti-inflammatory effect of atorvastatin with rosuvastatin in patients of acute coronary syndrome |
title_short | Comparison of anti-inflammatory effect of atorvastatin with rosuvastatin in patients of acute coronary syndrome |
title_sort | comparison of anti-inflammatory effect of atorvastatin with rosuvastatin in patients of acute coronary syndrome |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4544133/ https://www.ncbi.nlm.nih.gov/pubmed/26311995 http://dx.doi.org/10.4103/0976-500X.162011 |
work_keys_str_mv | AT khuranasushant comparisonofantiinflammatoryeffectofatorvastatinwithrosuvastatininpatientsofacutecoronarysyndrome AT guptasurabhi comparisonofantiinflammatoryeffectofatorvastatinwithrosuvastatininpatientsofacutecoronarysyndrome AT bhallahiralal comparisonofantiinflammatoryeffectofatorvastatinwithrosuvastatininpatientsofacutecoronarysyndrome AT nandwanishefali comparisonofantiinflammatoryeffectofatorvastatinwithrosuvastatininpatientsofacutecoronarysyndrome AT guptavarad comparisonofantiinflammatoryeffectofatorvastatinwithrosuvastatininpatientsofacutecoronarysyndrome |